Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
![Thumbnail](/bitstream/handle/internal/151/VDG1.pdf.jpg?sequence=7&isAllowed=y)
View/ Open
Date
2016-09ICR Author
Author
Vlenterie, M
Hillebrandt-Roeffen, MHS
Schaars, EWM
Flucke, UE
Fleuren, EDG
Navis, AC
Leenders, WPJ
Versleijen-Jonkers, YMH
van der Graaf, WTA
Type
Journal Article
Metadata
Show full item recordAbstract
Background In synovial sarcomas alterations in the cyclin D1-CDK4/6-Rb axis have been described. Also, β-catenin, a cyclin D1 regulator, is often overexpressed. Additionally, studies have shown that the t(X;18) translocation influences tumor behavior partly through cyclin D1 activation. We investigated how alterations in the cyclin D1-CDK4/6-Rb axis impact prognosis and studied effects of targeting this axis with the CDK4/6 inhibitor palbociclib.Methods Synovial sarcoma samples (n = 43) were immunohistochemically stained for β-catenin, cyclin D1, p16, p21, p27, Rb, and phospho-Rb. Fluorescent in situ hybridization (FISH) was performed to detect CCND1 amplification or translocation. In 4 synovial sarcoma cell lines sensitivity to palbociclib was investigated using cell viability assays, and effects on the sensitive cell lines were evaluated on protein level and by cell cycle arrest.Results Expression of nuclear phospho-Rb and nuclear β-catenin in the patient samples was associated with poor survival. FISH showed a sporadic translocation of CCND1 in a subset of tumors. An 8-fold CCND1 amplification was found in 1 cell line, but not in the patient samples investigated. Palbociclib effectively inhibited Rb-phosphorylation in 3 cell lines, resulting in an induction of a G1 arrest and proliferation block.Conclusions In this series nuclear phospho-Rb and nuclear β-catenin expression were negative prognostic factors. In vitro data suggest that palbociclib may be a potential treatment for a subset of synovial sarcoma patients. Whether this effect can be enhanced by combination treatment deserves further preclinical investigations.
Collections
Subject
Cell Line, Tumor
Humans
Sarcoma, Synovial
Piperazines
Pyridines
Cyclin D1
Retinoblastoma Protein
Antineoplastic Agents
Immunohistochemistry
Survival Rate
Cell Proliferation
Phosphorylation
Adolescent
Female
Male
Cyclin-Dependent Kinase Inhibitor p16
Cyclin-Dependent Kinase Inhibitor p21
Cyclin-Dependent Kinase Inhibitor p27
beta Catenin
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
Young Adult
G1 Phase Cell Cycle Checkpoints
Research team
Clinical and Translational Sarcoma
Language
eng
License start date
2016-09
Citation
Annals of surgical oncology, 2016, 23 (9), pp. 2745 - 2752
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A systematic review and meta-analysis.
Becherini, C; Visani, L; Caini, S; Bhattacharya, IS; Kirby, AM; et al. (ELSEVIER SCI LTD, 2023-09-01)The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have become the standard of care for hormone receptor-positive (HR + ) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, improving ... -
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman, MEM; Poon, E; Ebus, ME; den Hartog, IJM; van Noesel, CJM; et al. (AMER ASSOC CANCER RESEARCH, 2015-11-15)PURPOSE: MYCN-dependent neuroblastomas have low cure rates with current multimodal treatment regimens and novel therapeutic drugs are therefore urgently needed. In previous preclinical studies, we have shown that targeted ... -
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, SR; Mallinger, A; Workman, P; Clarke, PA (PERGAMON-ELSEVIER SCIENCE LTD, 2017-05-01)Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from observations that different CDK isoforms have ...